Abstract
Early clinical trials using murine double minute 2 (MDM2) inhibitors demonstrated proof-of-concept of p53-induced apoptosis by MDM2 inhibition in cancer cells; however, not all wild-type TP53 tumors are sensitive to MDM2 inhibition. Therefore, more potent inhibitors and biomarkers predictive of tumor sensitivity are needed. The novel MDM2 inhibitor DS-3032b is 10-fold more potent than the first-generation inhibitor nutlin-3a. TP53 mutations were predictive of resistance to DS-3032b, and allele frequencies of TP53 mutations were negatively correlated with sensitivity to DS-3032b. However, sensitivity to DS-3032b of TP53 wild-type tumors varied greatly. We thus used two methods to create predictive gene signatures. First, by comparing sensitivity to MDM2 inhibition with basal mRNA expression profiles in 240 cancer cell lines, a 175-gene signature was defined and validated in patient-derived tumor xenograft models and ex vivo human acute myeloid leukemia (AML) cells. Second, an AML-specific 1,532-gene signature was defined by performing random forest analysis with cross-validation using gene expression profiles of 41 primary AML samples. The combination of TP53 mutation status with the two gene signatures provided the best positiv...Continue Reading
References
Jul 22, 1998·Nucleic Acids Research·J MomandJ Niland
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu
Jul 15, 2005·Blood·Kensuke KojimaMichael Andreeff
Feb 5, 2010·Cancer Cell·Roel G W VerhaakUNKNOWN Cancer Genome Atlas Research Network
Apr 21, 2010·Blood·Jianting LongSami N Malek
Oct 23, 2012·The Lancet Oncology·Isabelle Ray-CoquardBinh Nguyen Bui
Jan 11, 2013·Nature Reviews. Cancer·Mark WadeGeoffrey M Wahl
Feb 13, 2013·Cancer Research·Christian TovarLyubomir T Vassilev
May 21, 2013·Cell Reports·Zdenek AndrysikJoaquín M Espinosa
Jul 3, 2013·Journal of Medicinal Chemistry·Qingjie DingBradford Graves
Feb 3, 2015·Molecular Cell·Peiying YePan Zheng
Apr 10, 2015·British Journal of Haematology·Hua ZhongWilliam E Pierceall
Apr 18, 2015·Bioorganic & Medicinal Chemistry·Masaki MiyazakiTsunehiko Soga
May 13, 2015·ELife·Sébastien JeayDiana Graus Porta
Sep 17, 2015·PloS One·Jo IshizawaMichael Andreeff
Oct 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael AndreeffKensuke Kojima
Oct 23, 2015·ELife·Dmitriy Sonkin
Feb 13, 2016·Haematologica·Bernard ReisWilliam E Pierceall
Feb 18, 2016·Science Signaling·Jo IshizawaMichael Andreeff
Mar 14, 2017·Oncogene·M Fischer
Jun 14, 2017·Blood·Miron ProkocimerVarda Rotter
Sep 9, 2017·Cell·Edward R Kastenhuber, Scott W Lowe
Citations
Jul 17, 2019·Journal of Molecular Cell Biology·Gema SanzGalina Selivanova
Oct 7, 2019·Medicinal Research Reviews·Wei WangRuiwen Zhang
Jun 24, 2020·Journal of Biophotonics·Brandon S NicholsNirmala Ramanujam
Aug 17, 2020·Nucleic Acids Research·Morgan A SammonsMartin Fischer
Jul 12, 2020·Leukemia·Marina KonoplevaMichael Andreeff
Oct 28, 2019·Nature Communications·Yasutaka HayashiToshio Kitamura
Dec 3, 2020·Leukemia·Thi Thanh VuDavid D Ma
Feb 6, 2020·Cancer Discovery·Nicholas J ShortNaval Daver
Aug 4, 2020·Seminars in Cancer Biology·Michael J DuffyJohn Crown
Nov 7, 2020·Molecular Cancer Research : MCR·Manman DengKen H Young
Mar 25, 2021·Journal of Hematology & Oncology·Hongtao Liu
May 1, 2021·Cancers·Magdalena C Liebl, Thomas G Hofmann
Jul 27, 2021·Frontiers in Oncology·Xanthene MilesJulie Bolcaen